1. Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
- Author
-
Nicolas Lambert, Dominique Dive, Solène Dauby, Pierre Maquet, and Bernard Sadzot
- Subjects
atezolizumab ,Microbiology (medical) ,Epidemiology ,animal diseases ,medicine.medical_treatment ,JC virus ,chemical and pharmacologic phenomena ,Infectious and parasitic diseases ,RC109-216 ,Antibodies, Monoclonal, Humanized ,Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy ,medicine.disease_cause ,progressive multifocal leukoencephalopathy ,Belgium ,Immune reconstitution inflammatory syndrome ,Atezolizumab ,Immunity ,Research Letter ,Humans ,Medicine ,viruses ,Adverse effect ,Radiologic Response ,business.industry ,Progressive multifocal leukoencephalopathy ,Leukoencephalopathy, Progressive Multifocal ,Immunotherapy ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,immune reconstitution inflammatory syndrome ,Infectious Diseases ,Immunology ,bacteria ,immunotherapy ,business - Abstract
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.
- Published
- 2022
- Full Text
- View/download PDF